BACKGROUND: Neuroblastoma is a paediatric cancer which originates from precursor cells of the sympathetic nervous system. Previous studies have shown that miR-184 expression has anti-proliferative effects in neuroblastoma cells grown in culture. Therefore, it was of interest to evaluate this effect in vivo. MATERIALS AND METHODS: Neuroblastoma cells overexpressing miR-184 were injected retroperitoneally into CB17-SCID mice and tumour burden was assessed by measuring bioluminescence. Overall survival was also evaluated. RESULTS: Ectopic overexpression of miR-184 in neuroblastoma cell lines is anti-proliferative. In addition, overexpression of miR-184 led to a significant reduction in tumour growth relative to negative control-treated cohorts in a xenograft model of neuroblastoma. CONCLUSION: This study demonstrated for the first time that miR-184 significantly reduces tumour growth and increases overall survival in an orthotopic murine model of neuroblastoma through assessment of tumour growth and moribundity relative to control miRNA-treated cohorts.
BACKGROUND:Neuroblastoma is a paediatric cancer which originates from precursor cells of the sympathetic nervous system. Previous studies have shown that miR-184 expression has anti-proliferative effects in neuroblastoma cells grown in culture. Therefore, it was of interest to evaluate this effect in vivo. MATERIALS AND METHODS:Neuroblastoma cells overexpressing miR-184 were injected retroperitoneally into CB17-SCID mice and tumour burden was assessed by measuring bioluminescence. Overall survival was also evaluated. RESULTS: Ectopic overexpression of miR-184 in neuroblastoma cell lines is anti-proliferative. In addition, overexpression of miR-184 led to a significant reduction in tumour growth relative to negative control-treated cohorts in a xenograft model of neuroblastoma. CONCLUSION: This study demonstrated for the first time that miR-184 significantly reduces tumour growth and increases overall survival in an orthotopic murine model of neuroblastoma through assessment of tumour growth and moribundity relative to control miRNA-treated cohorts.
Authors: Raymond L Stallings; Niamh H Foley; Kenneth Bryan; Patrick G Buckley; Isabella Bray Journal: Expert Opin Ther Targets Date: 2010-09 Impact factor: 6.902
Authors: Paxton V Dickson; Blair Hamner; Catherine Y C Ng; Marshall M Hall; Junfang Zhou; Phillip W Hargrove; M Beth McCarville; Andrew M Davidoff Journal: J Pediatr Surg Date: 2007-07 Impact factor: 2.545
Authors: Isabella Bray; Kenneth Bryan; Suzanne Prenter; Patrick G Buckley; Niamh H Foley; Derek M Murphy; Leah Alcock; Pieter Mestdagh; Jo Vandesompele; Frank Speleman; Wendy B London; Patrick W McGrady; Desmond G Higgins; Anne O'Meara; Maureen O'Sullivan; Raymond L Stallings Journal: PLoS One Date: 2009-11-16 Impact factor: 3.240
Authors: Jingbo Qiao; Sora Lee; Pritha Paul; Lauren Theiss; Joshua Tiao; Lan Qiao; Andrew Kong; Dai H Chung Journal: Surgery Date: 2013-06-24 Impact factor: 3.982
Authors: Jennifer Lynch; Joanna Fay; Maria Meehan; Kenneth Bryan; Karen M Watters; Derek M Murphy; Raymond L Stallings Journal: Carcinogenesis Date: 2012-03-01 Impact factor: 4.944
Authors: Isabella Bray; Amanda Tivnan; Kenneth Bryan; Niamh H Foley; Karen M Watters; Lorraine Tracey; Andrew M Davidoff; Raymond L Stallings Journal: Cancer Lett Date: 2011-04-01 Impact factor: 8.679
Authors: Raymond L Stallings; Niamh H Foley; Isabella M Bray; Sudipto Das; Patrick G Buckley Journal: Semin Cancer Biol Date: 2011-07-13 Impact factor: 15.707
Authors: Palanisamy Nallasamy; Srinivas Chava; Sumit S Verma; Shruti Mishra; Santhi Gorantla; Don W Coulter; Siddappa N Byrareddy; Surinder K Batra; Subash C Gupta; Kishore B Challagundla Journal: Semin Cancer Biol Date: 2017-11-28 Impact factor: 15.707
Authors: S Das; K Bryan; P G Buckley; O Piskareva; I M Bray; N Foley; J Ryan; J Lynch; L Creevey; J Fay; S Prenter; J Koster; P van Sluis; R Versteeg; A Eggert; J H Schulte; A Schramm; P Mestdagh; J Vandesompele; F Speleman; R L Stallings Journal: Oncogene Date: 2012-07-16 Impact factor: 9.867